(DEMANT) Demant - Ratings and Ratios
Hearing Aids, Hearing Care, Assessment
DEMANT EPS (Earnings per Share)
DEMANT Revenue
Description: DEMANT Demant
Demant A/S is a leading hearing healthcare company with a global presence, operating in multiple regions including Europe, North America, Asia, and the Pacific. The company develops, manufactures, and distributes hearing aids and personalized hearing care products, as well as provides hearing and balance assessment solutions for healthcare professionals.
With a rich history dating back to 1904, Demant A/S has established itself as a prominent player in the healthcare equipment industry, particularly in the hearing care segment. The companys product portfolio and solutions cater to the needs of audiologists, ENT doctors, and balance clinics, making it a key partner in the healthcare ecosystem.
From a financial perspective, Demant A/S has demonstrated strong performance, with a market capitalization of approximately DKK 56.15 billion. The companys return on equity (RoE) stands at 32.47%, indicating a high level of profitability. Additionally, the price-to-earnings (P/E) ratio is around 19.79, suggesting a reasonable valuation. Other key performance indicators (KPIs) that can be considered include revenue growth, gross margin, and operating profit margin, which are essential in evaluating the companys financial health and competitiveness.
Further analysis of Demant A/Ss KPIs reveals that the companys dividend yield and payout ratio are also important metrics to consider. A stable and growing dividend can indicate a companys ability to generate consistent cash flows and return value to shareholders. Moreover, the companys debt-to-equity ratio and interest coverage ratio can provide insights into its capital structure and ability to meet its financial obligations.
DEMANT Stock Overview
| Market Cap in USD | 9,304m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
DEMANT Stock Ratings
| Growth Rating | 3.19 |
| Fundamental | 70.2% |
| Dividend Rating | 3.49 |
| Rel. Strength | 11.4 |
| Analysts | - |
| Fair Price Momentum | 232.58 DKK |
| Fair Price DCF | 401.17 DKK |
DEMANT Dividends
Currently no dividends paidDEMANT Growth Ratios
| Growth Correlation 3m | 8% |
| Growth Correlation 12m | -31.8% |
| Growth Correlation 5y | 4.4% |
| CAGR 5y | 5.13% |
| CAGR/Max DD 5y | 0.09 |
| Sharpe Ratio 12m | -0.14 |
| Alpha | -18.28 |
| Beta | 0.636 |
| Volatility | 34.46% |
| Current Volume | 319.3k |
| Average Volume 20d | 134.1k |
| Stop Loss | 248.5 (-3%) |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (3.06b TTM) > 0 and > 6% of Revenue (6% = 1.68b TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA -0.50pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.63% (prev 7.88%; Δ 5.74pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 4.65b > Net Income 3.06b (YES >=105%, WARN >=100%) |
| Net Debt (11.80b) to EBITDA (4.77b) ratio: 2.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (213.0m) change vs 12m ago -4.52% (target <= -2.0% for YES) |
| Gross Margin 75.24% (prev 73.73%; Δ 1.51pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 89.15% (prev 104.7%; Δ -15.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.56 (EBITDA TTM 4.77b / Interest Expense TTM 912.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.60
| (A) 0.12 = (Total Current Assets 9.92b - Total Current Liabilities 6.09b) / Total Assets 32.45b |
| (B) 0.29 = Retained Earnings (Balance) 9.38b / Total Assets 32.45b |
| (C) 0.13 = EBIT TTM 4.16b / Avg Total Assets 31.50b |
| (D) 0.0 = Book Value of Equity 0.0 / Total Liabilities 22.81b |
| Total Rating: 2.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.16
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 5.09% = 2.54 |
| 3. FCF Margin 12.93% = 3.23 |
| 4. Debt/Equity 1.35 = 1.65 |
| 5. Debt/Ebitda 2.71 = -1.32 |
| 6. ROIC - WACC 7.00% = 8.75 |
| 7. RoE 32.47% = 2.50 |
| 8. Rev. Trend 9.64% = 0.48 |
| 9. Rev. CAGR 6.57% = 0.82 |
| 10. EPS Trend data missing |
| 11. EPS CAGR 0.0% = 0.0 |
As of August 11, 2025, the stock is trading at DKK 256.20 with a total of 319,318 shares traded.
Over the past week, the price has changed by +2.89%, over one month by -4.97%, over three months by -0.16% and over the past year by -1.31%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Demant (CO:DEMANT) is currently (August 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 70.16 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DEMANT is around 232.58 DKK . This means that DEMANT is currently overvalued and has a potential downside of -9.22%.
Demant has no consensus analysts rating.
According to our own proprietary Forecast Model, DEMANT Demant will be worth about 256.5 in August 2026. The stock is currently trading at 256.20. This means that the stock has a potential upside of +0.1%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 296.4 | 15.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 256.5 | 0.1% |
DEMANT Fundamental Data Overview
Market Cap DKK = 59.60b (59.60b DKK * 1.0 DKK.DKK)
CCE Cash And Equivalents = 1.11b DKK (Cash only, last quarter)
P/E Trailing = 21.006
P/E Forward = 20.7039
P/S = 2.6585
P/B = 6.2318
P/EG = 0.9895
Beta = 0.904
Revenue TTM = 28.08b DKK
EBIT TTM = 4.16b DKK
EBITDA TTM = 4.77b DKK
Long Term Debt = 12.49b DKK (from longTermDebt, last quarter)
Short Term Debt = 423.0m DKK (from shortLongTermDebt, last quarter)
Debt = 12.91b DKK (Calculated: Short Term 423.0m + Long Term 12.49b)
Net Debt = 11.80b DKK (from netDebt column, last quarter)
Enterprise Value = 71.40b DKK (59.60b + Debt 12.91b - CCE 1.11b)
Interest Coverage Ratio = 4.56 (Ebit TTM 4.16b / Interest Expense TTM 912.0m)
FCF Yield = 5.09% (FCF TTM 3.63b / Enterprise Value 71.40b)
FCF Margin = 12.93% (FCF TTM 3.63b / Revenue TTM 28.08b)
Net Margin = 10.90% (Net Income TTM 3.06b / Revenue TTM 28.08b)
Gross Margin = 75.24% ((Revenue TTM 28.08b - Cost of Revenue TTM 6.95b) / Revenue TTM)
[93m Tobins Q-Ratio = unknown (Enterprise Value 71.40b / Book Value Of Equity 0.0)
[39m Interest Expense / Debt = 3.59% (Interest Expense 463.0m / Debt 12.91b)
Taxrate = 24.02% (from quarterly Income Tax Expense: 214.0m / 891.0m)
NOPAT = 3.16b (EBIT 4.16b * (1 - 24.02%))
Current Ratio = 1.63 (Total Current Assets 9.92b / Total Current Liabilities 6.09b)
Debt / Equity = 1.35 (Debt 12.91b / last Quarter total Stockholder Equity 9.56b)
Debt / EBITDA = 2.71 (Net Debt 11.80b / EBITDA 4.77b)
Debt / FCF = 3.56 (Debt 12.91b / FCF TTM 3.63b)
Total Stockholder Equity = 9.42b (last 4 quarters mean)
RoA = 9.43% (Net Income 3.06b, Total Assets 32.45b )
RoE = 32.47% (Net Income TTM 3.06b / Total Stockholder Equity 9.42b)
RoCE = 18.98% (Ebit 4.16b / (Equity 9.42b + L.T.Debt 12.49b))
RoIC = 14.36% (NOPAT 3.16b / Invested Capital 22.01b)
WACC = 7.36% (E(59.60b)/V(72.51b) * Re(8.36%)) + (D(12.91b)/V(72.51b) * Rd(3.59%) * (1-Tc(0.24)))
Shares Correlation 5-Years: -100.0 | Cagr: -1.80%
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 78.39% ; FCFE base≈3.61b ; Y1≈4.03b ; Y5≈5.31b
Fair Price DCF = 401.2 (DCF Value 85.45b / Shares Outstanding 213.0m; 5y FCF grow 13.44% → 2.90% )
Revenue Correlation: 9.64 | Revenue CAGR: 6.57%
Revenue Growth Correlation: -64.70%
EPS Correlation: N/A | EPS CAGR: 0.0%
EPS Growth Correlation: -36.76%